Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Name:	us-gaap_FiniteLivedLicenseAgreementsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Note 5 - Commitments (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Note 5 - Commitments (Details Textual) - USD ($)	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Mar. 31, 2021	Apr. 30, 2020	Dec. 31, 2016
The Constructs [Member]
Maximum Contingent Obligation						$ 356,000,000
Payments for Milestone, Royalty and Sublicensing	$ 0	$ 0	$ 0	$ 0
License Agreement Related to Pharmaceutical Products [Member]
Maximum Contingent Obligation							$ 18,400,000
Finite-Lived License Agreements, Gross						$ 0
License Agreement to Acquire Global Rights of Pharmaceutical Product [Member]
Maximum Contingent Obligation					$ 68,900,000
Milestone Expense	$ 25,000		$ 75,000